Chemical molecular structures representing the science behind tesamorelin GHRH therapy at Rewind Anti-Aging Miami
FDA-Approved GHRH Analog

Tesamorelin Therapy in Miami

Target visceral abdominal fat with tesamorelin — an FDA-approved GHRH analog with clinical data demonstrating significant trunk fat reduction. Prescribed at Rewind Anti-Aging of Miami for body composition optimization.

Medically Supervised Data-Driven Treatment Personalized Protocols Ongoing Monitoring

What Is Tesamorelin?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) — the hypothalamic hormone that signals the pituitary gland to produce and release human growth hormone (HGH). It is marketed under the brand name Egrifta and holds the distinction of being the only GHRH analog with FDA approval specifically for the reduction of visceral abdominal fat.

Originally developed for the treatment of lipodystrophy in HIV-positive patients, clinical trials demonstrated that tesamorelin significantly reduced visceral adipose tissue (VAT). Its efficacy has led to growing off-label use in the broader anti-aging and body composition optimization space. Explore the full range of tesamorelin benefits supported by clinical research.

At Rewind Anti-Aging of Miami, we prescribe tesamorelin for patients who want to specifically target visceral abdominal fat — the deep, metabolically active fat that surrounds the organs and drives cardiovascular risk, insulin resistance, and systemic inflammation.

Doctor preparing tesamorelin peptide injection at Rewind Anti-Aging Miami

Why Visceral Fat Matters

Not all body fat is equal. Visceral fat — the fat deep in the abdominal cavity surrounding the organs — is metabolically active tissue that functions like an endocrine organ, releasing inflammatory compounds that drive disease.

Insulin Resistance & Type 2 Diabetes

Visceral fat impairs insulin signaling and glucose metabolism, driving insulin resistance and increasing diabetes risk.

Cardiovascular Disease

Inflammatory molecules released by visceral fat promote atherosclerosis and elevated blood pressure.

Systemic Inflammation

One of the primary sources of chronic, low-grade inflammation that accelerates aging.

Hormonal Disruption

Contains high concentrations of aromatase, converting testosterone to estrogen and contributing to hormonal imbalance in both men and women.

Fatty Liver Disease

Excess visceral fat is closely associated with non-alcoholic fatty liver disease (NAFLD).

Reducing visceral fat is one of the highest-impact interventions for cardiometabolic health, and tesamorelin has clinical evidence supporting its ability to do so.

How Tesamorelin Works

Tesamorelin is a modified version of the natural GHRH peptide with a trans-3-hexenoic acid group that increases stability and resistance to enzymatic degradation, making it more potent and longer-acting than native GHRH.

When injected, tesamorelin binds to GHRH receptors on the pituitary gland, stimulating the release of endogenous growth hormone. The resulting increase in HGH and IGF-1 produces:

  • Lipolysis — breakdown of stored triglycerides in adipose tissue, with particular affinity for visceral fat depots
  • Reduced lipogenesis — inhibits the storage of new fat in visceral compartments
  • Improved body composition — simultaneously supports lean muscle preservation while reducing fat mass
  • Metabolic improvement — improvements in triglycerides and cholesterol profiles

Proven Visceral Fat Reduction

Tesamorelin has been evaluated in multiple randomized, placebo-controlled clinical trials. These results are notable because visceral fat is notoriously resistant to reduction through diet and exercise alone.

15-18%

Average reduction in visceral adipose tissue over 26 weeks, measured by CT scan

IGF-1

Increased IGF-1 levels confirming growth hormone stimulation

Lipids

Improvements in triglyceride levels and total cholesterol-to-HDL ratio

Sustained

Trunk fat reduction maintained with continued therapy, reversed upon discontinuation

Tesamorelin vs. Sermorelin

Both are GHRH analogs that stimulate the pituitary to release growth hormone. The right choice depends on your primary goal.

Factor Tesamorelin Sermorelin
Potency Higher — trans-3-hexenoic acid modification increases stability Standard GHRH analog potency
Fat reduction evidence FDA-approved with robust clinical trial data for visceral fat Broader anti-aging applications, less specific fat data
Best for Visceral abdominal fat is the primary concern General anti-aging, sleep, overall GH optimization
Cost Generally more expensive More affordable for long-term protocols

For patients whose primary goal is visceral fat reduction, tesamorelin is the stronger option. For broader anti-aging and growth hormone optimization, sermorelin or other peptides may be more appropriate — or the two can be used sequentially.

Administration

Treatment Protocol

Tesamorelin is administered as a once-daily subcutaneous injection, typically in the abdominal area.

Injection type

Subcutaneous, using a small insulin-type syringe

Frequency

Once daily, typically in the evening before bed

Duration

Minimum 26 weeks (6 months) based on clinical trial data

Monitoring

IGF-1, fasting glucose, hemoglobin A1c, and body composition tracked throughout

Safety Profile

Side Effects

  • Injection site reactions — Redness, itching, or mild irritation at the injection site. Most commonly reported.
  • Joint pain — Related to growth hormone's effects on fluid and connective tissue. Usually mild and dose-dependent.
  • Peripheral edema — Mild swelling in the hands or feet, typically transient.
  • Elevated blood sugar — Growth hormone reduces insulin sensitivity. Fasting glucose and A1c are monitored during therapy.
  • Headache and muscle pain — Occasionally reported, usually mild.

Contraindications: Tesamorelin should not be used by patients with active cancer, patients with disruption of the hypothalamic-pituitary axis due to surgery or radiation, or women who are pregnant or breastfeeding.

Frequently Asked Questions About Tesamorelin

What is tesamorelin FDA-approved for?

Tesamorelin is FDA-approved under the brand name Egrifta for the reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients with lipodystrophy syndrome. It is the only GHRH analog with a specific FDA approval for visceral fat reduction. At Rewind Anti-Aging of Miami, we prescribe tesamorelin off-label for patients without HIV who are seeking targeted reduction of visceral abdominal fat as part of a comprehensive body composition and anti-aging program.

How does tesamorelin differ from sermorelin?

Both tesamorelin and sermorelin are growth hormone-releasing hormone (GHRH) analogs that stimulate the pituitary gland to produce HGH. The key difference is potency and specificity. Tesamorelin is a modified GHRH analog with a trans-3-hexenoic acid group that increases its stability and potency. Clinical data specifically demonstrates tesamorelin's ability to reduce visceral abdominal fat — an effect that is more pronounced and better documented than with sermorelin. Sermorelin is a broader-spectrum growth hormone peptide commonly used for general anti-aging, sleep, and body composition. Tesamorelin is the stronger choice when visceral fat reduction is the primary goal.

How long does it take to see results from tesamorelin?

Most patients begin to notice improvements in body composition within 8 to 12 weeks of consistent daily injections. Clinical trials demonstrated significant reductions in trunk fat by week 26 (six months). The timeline depends on baseline visceral fat levels, adherence to the daily injection protocol, diet and exercise habits, and overall hormonal health. Tesamorelin works best as part of a comprehensive approach that includes nutrition optimization and regular physical activity.

Do I need to inject tesamorelin every day?

Yes. Tesamorelin is administered as a once-daily subcutaneous injection, typically in the abdominal area. The injection uses a small insulin-type needle and takes only seconds. Most patients become comfortable with the self-injection process within the first few days. Consistency is critical — the fat-reducing and body composition benefits require daily stimulation of growth hormone release. Missing doses reduces the cumulative effect of therapy.

What are the side effects of tesamorelin?

The most common side effects include injection site reactions (redness, itching, or irritation), joint pain, and peripheral edema (mild swelling in the hands or feet). Less common side effects include headache, muscle pain, and elevated blood sugar. Because tesamorelin stimulates growth hormone, it can affect insulin sensitivity — fasting glucose and hemoglobin A1c are monitored during therapy. Tesamorelin should not be used by patients with active cancer, as growth hormone can promote cell proliferation.

Can tesamorelin be combined with other peptides?

Yes. Tesamorelin can be combined with other peptides for enhanced results. Common combinations include tesamorelin with ipamorelin (which stimulates GH release through the ghrelin receptor, complementing tesamorelin's GHRH pathway), and tesamorelin with BPC-157 or TB-500 for patients who also have tissue healing needs. It can also be used alongside testosterone therapy and other hormone optimization protocols. Your provider will design a protocol based on your specific goals.

Target Visceral Fat at Its Source

Tesamorelin offers clinically proven visceral fat reduction through growth hormone optimization. Schedule a consultation to discuss your body composition goals.

Explore all Peptide Therapy options →

See real patient results →

See how your treatment is designed →

Medical Director: Dr. Jeffrey C. Lombardo, M.D. Reviewed by Alexia Padron, MSN, APRN, FNP-BC Last reviewed: April 2026

Medical Disclaimer

The information on this page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. All treatments at Rewind Anti-Aging of Miami are performed under the supervision of licensed medical professionals. Individual results may vary. Consult your physician before beginning any new treatment protocol.

Meet our clinical team →

Areas We Serve in Miami & South Florida

Our Wynwood clinic at 24 NW 29th Street serves patients across the Miami metro in person and the entire state of Florida via telehealth.

View all service areas →

Chat with Rewind AI

We typically reply instantly

Powered by AI — not medical advice
Book Consultation